Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study

Starting soon

Conditions studied: Dyslipidemia

In brief

This study is a prospective, non-interventional, multi-center observational study to evaluate the efficacy and safety of Baroezet Tablet 1/10 mg in Korean patients with dyslipidemia in real-world clinical practice. Patients who are prescribed Baroezet Tablet according to the physician's clinical judgment will be followed for approximately 24 weeks. The study will assess changes in lipid profiles, including LDL-C, as well as safety outcomes such as adverse events.

Key facts

Study ID

NCT07515560

Run by

Daewoong Pharmaceutical Co. LTD.

People needed

12000

Starts

2026-04-30

Expected to finish

2027-12-31

Last updated by the study team

2026-04-07

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged ≥19 years
• Patients diagnosed with dyslipidemia
• Patients who require treatment with Baroezet Tablet
• Patients who provide written informed consent

You may not qualify if…

• Hypersensitivity to study drug components
• Active liver disease
• Pregnant or breastfeeding women
• Patients considered inappropriate by investigator

Where it is running

• Multiple centers in Republic of Korea — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.